title: Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects.
abstract: It is well known that GH responses to GH-releasing hormone (GHRH) show marked interindividual variations in normal subjects, which have been attributed to a variable somatostatinergic tone. Recently, it has been shown that enhancement of cholinergic tone with the acetylcholinesterase inhibitor pyridostigmine (PD), which presumably acts by inhibiting somatostatin release, stimulates basal GH secretion and GH responses to a maximal dose of GHRH. In this study we have investigated the effects of PD on the dose-response relationships of GHRH-induced GH secretion in normal subjects. Our data showed that PD (120 mg, orally, at-60 min) induced a clear-cut increase in basal GH levels, significantly different from that after saline treatment, at 15, 30, 45, 60, 90, and 120 min. Moreover, PD administration markedly potentiated GH responses to GHRH at doses of 500, 100, 25, 10, and 3 micrograms/subject, as assessed by either area under the curve or maximal peak GH levels. In fact, GH responses to pyridostigmine plus 3 micrograms GHRH were similar to those to the administration of 500 and 100 micrograms GHRH alone. Our findings of marked increases in GH response to GHRH after pyridostigmine administration show that with enhancement of cholinergic tone, the dose of GHRH needed to induce a similar increase in GH is reduced 30 times.
authors.affiliation: Department of Medicine, Facultad de Medicina, Santiago de Compostela, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Peñalva
authors.forename: C
authors.initials: C
authors.lastname: Muruais
authors.forename: F F
authors.initials: FF
authors.lastname: Casanueva
authors.forename: C
authors.initials: C
authors.lastname: Dieguez
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D013006:Growth Hormone / Q000097:blood* / Q000378:metabolism; D013007:Growth Hormone-Releasing Hormone / Q000494:pharmacology*; D006801:Humans; D008297:Male; D011729:Pyridostigmine Bromide / Q000494:pharmacology*; D011976:Receptors, Muscarinic / Q000187:drug effects* / Q000502:physiology
chemical_list: D011976:Receptors, Muscarinic; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone; D011729:Pyridostigmine Bromide